The semaglutide vs tirzepatide vs retatrutide question is really a question about receptor coverage: one receptor, two, or three. Semaglutide is a GLP-1 mono-agonist, tirzepatide a GIP/GLP-1 dual agonist and retatrutide a GLP-1/GIP/glucagon triple agonist. This guide compares the three molecules on structure, receptor pharmacology, published trial programmes and laboratory handling, for researchers selecting a reference compound.
Key takeaways
- Receptor coverage is the defining difference: semaglutide engages GLP-1R only; tirzepatide adds GIPR; retatrutide adds the glucagon receptor (GCGR) on top of both.
- Backbone origin differs too. Semaglutide is built on GLP-1(7-37); tirzepatide and retatrutide are 39-residue molecules built on a GIP-derived scaffold.
- All three use the same persistence strategy — an α-aminoisobutyric acid (Aib) substitution to block DPP-4, plus a fatty diacid on a γGlu–AEEA linker for reversible albumin binding.
- Semaglutide: CAS 910463-68-2, C187H291N45O59, MW 4113.6 Da. Tirzepatide: CAS 2023788-19-2, C225H348N48O68, MW ≈4813 Da. Retatrutide: CAS 2381089-83-2, C221H342N46O68, MW ≈4731 Da.
- Tirzepatide is an imbalanced agonist: near-native potency at GIPR but weaker and G-protein-biased at GLP-1R, so it is not equivalent to co-administering two selective agonists.
- The published trial programmes — STEP for semaglutide, SURMOUNT and SURPASS for tirzepatide, and the 2023 phase 2 trial for retatrutide — report progressively larger effects as receptor coverage widens.
- Handling is essentially identical across the three: all are acylated, surface-active peptides that must not be shaken, foamed or repeatedly frozen and thawed.
Semaglutide vs tirzepatide vs retatrutide at a glance
In a semaglutide vs tirzepatide vs retatrutide comparison the three molecules form a clean pharmacological series. Each adds a receptor arm to the one before it, while keeping broadly the same chemistry for stability. That makes the trio unusually well suited to experiments that isolate the contribution of individual incretin receptors.
Semaglutide is the mono-agonist reference. It is a 31-residue GLP-1 analogue with a single receptor target and the most extensively characterised structure–activity relationship of the three, described in the original medicinal-chemistry paper by Lau and colleagues.2
Tirzepatide is a 39-residue molecule whose backbone derives from GIP rather than GLP-1, engineered so that it retains sufficient GLP-1R recognition to activate that receptor as well.3 Retatrutide extends the same architectural idea to a third receptor, engaging GCGR alongside GIPR and GLP-1R.7
Receptor targets: one, two or three
Each receptor arm contributes distinct physiology in the published literature, which is why adding arms changes the pharmacological profile rather than simply increasing potency. Understanding what each arm is thought to do is the foundation of any comparison between these three compounds.
The GLP-1 receptor arm is the best characterised. Drucker’s review sets out the glucose-dependent insulinotropic mechanism at the beta cell, the hindbrain and hypothalamic receptor populations implicated in food-intake regulation, and the effect on gastric motility.1 Every one of the three compounds engages this arm.
The GIP receptor arm is more complex. GIPR is expressed in adipose tissue and at central sites, and the pharmacology of GIPR agonism has been the subject of sustained debate. What receptor-level work has established is that tirzepatide behaves close to native GIP at GIPR while being substantially weaker than native GLP-1 at GLP-1R.3,4
The glucagon receptor arm, unique to retatrutide among these three, is generally discussed in terms of hepatic glucose and lipid handling and a contribution to energy expenditure. Adding a GCGR component is pharmacologically delicate: the glucagon and GLP-1 arms have opposing effects on glycaemia, so the balance between them is a deliberate design parameter rather than an accident.
Structural comparison: backbone, Aib and acylation
All three molecules solve the same two chemical problems — DPP-4 cleavage and rapid renal clearance — using the same two tools, but they apply them to different backbones and at different positions.
Semaglutide’s modifications
Semaglutide carries three changes relative to native GLP-1(7-37): Aib replaces alanine at position 8, arginine replaces lysine at position 34, and the lysine at position 26 carries a C18 diacid attached through a γ-glutamic acid unit and two AEEA spacers. The Arg34 substitution exists to make the acylation site-specific; without it the chemistry could attach the fatty acid to the wrong lysine.2
Tirzepatide’s and retatrutide’s modifications
Tirzepatide is a 39-residue peptide with a C-terminal amide, two Aib residues (positions 2 and 13) and a C20 diacid on the lysine at position 20, again through a γGlu–AEEA linker. Retatrutide shares this general architecture — a 39-residue GIP-derived backbone with Aib substitutions and fatty-diacid acylation — with sequence changes that introduce glucagon-receptor recognition.
Head-to-head specification table
The table below collects the identity and pharmacology data for the three compounds. Molecular weights are monoisotopic-adjacent average values as reported by chemical suppliers and databases; researchers should always confirm against the mass reported on the batch certificate of analysis.
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Class | GLP-1 mono-agonist | GIP/GLP-1 dual agonist | GLP-1/GIP/GCGR triple agonist |
| Development code | NN9535 | LY3298176 | LY3437943 |
| CAS number | 910463-68-2 | 2023788-19-2 | 2381089-83-2 |
| Molecular formula | C187H291N45O59 | C225H348N48O68 | C221H342N46O68 |
| Molecular weight | 4113.6 Da | ≈4813 Da | ≈4731 Da |
| Residue count | 31 | 39 | 39 |
| Backbone origin | GLP-1(7-37) | GIP | GIP |
| DPP-4 blocking residue | Aib8 | Aib2, Aib13 | Aib substitutions |
| Acylation | C18 diacid at Lys26 | C20 diacid at Lys20 | Fatty-diacid acylation |
| Linker | γGlu + 2×AEEA | γGlu + 2×AEEA | γGlu + AEEA spacers |
| C-terminus | Free acid | Amide | Amide |
| Reported half-life | ≈165 h | ≈117 h (≈5 days) | Supports weekly administration in trials |
| Physical form supplied | Lyophilised powder | Lyophilised powder | Lyophilised powder |
| Appearance in solution | Clear, colourless | Clear, colourless | Clear, colourless |
Receptor pharmacology and signalling bias
Potency at a receptor is not the whole story. A molecule can bind a receptor tightly, activate it only partially, and recruit some downstream effectors while neglecting others. All three of these behaviours have been documented in this compound class, and they are the reason a dual agonist is not interchangeable with two mono-agonists.
Coskun and colleagues reported that tirzepatide binds GIPR with an affinity comparable to native GIP but binds GLP-1R roughly five-fold more weakly than native GLP-1, with a corresponding potency gap in cyclic AMP accumulation assays.3 Willard and colleagues went further, showing that at GLP-1R tirzepatide is biased towards G-protein signalling over β-arrestin recruitment — a mechanistically distinct behaviour from that of GLP-1 mono-agonists.4
Sun and colleagues then provided the structural explanation, resolving how the GIP-derived scaffold makes the contacts required for GLP-1R activation while remaining optimised for GIPR.5
For retatrutide, published characterisation reports agonism at all three receptors with markedly different potencies — highest at GIPR, intermediate at GLP-1R, and lowest at GCGR.7 That deliberate imbalance is what allows a glucagon-receptor arm to be included without the glycaemic penalty that unopposed glucagon agonism would produce.
Published trial programmes compared
The three compounds have been examined in large randomised trials of their licensed pharmaceutical forms. The summary below is provided as research context only — it describes what has been published about these molecules, not any protocol for administration.
| Compound | Trial | Participants | Duration | Reported mean change in body weight | Ref |
|---|---|---|---|---|---|
| Semaglutide | STEP 1 | 1,961 adults | 68 weeks | −14.9% vs −2.4% with placebo | 6 |
| Tirzepatide | SURMOUNT-1 | 2,539 adults | 72 weeks | −15.0% to −20.9% across administered levels vs −3.1% with placebo | 8 |
| Retatrutide | Phase 2 obesity trial | 338 adults | 48 weeks | −8.7% to −24.2% across administered levels vs −2.1% with placebo | 7 |
| Tirzepatide vs semaglutide | SURPASS-2 (type 2 diabetes) | 1,878 adults | 40 weeks | HbA1c change −2.01% to −2.30% with tirzepatide vs −1.86% with semaglutide | Frías 2021 |
Two observations are worth drawing out. First, SURPASS-2 is the only direct randomised head-to-head between two of these molecules; comparisons between the semaglutide and retatrutide programmes are cross-trial and therefore weaker evidence. Second, the trials differ in duration, population and endpoint definition, so the numbers in Table 2 are not directly comparable across rows.
Retatrutide’s later-stage programme carries the TRIUMPH name, but the phase 2 data cited here are from the 2023 trial reported by Jastreboff and colleagues.7
Handling and solution preparation
Handling is functionally identical across all three. They are acylated, amphipathic peptides supplied as lyophilised powder, and the same three failure modes account for most unexplained potency loss: foaming, adsorption to plastic, and repeated freeze–thaw.
- Warm the sealed vial. Bring it to ambient temperature before removing the flip cap so moisture does not condense on the cake.
- Add diluent slowly down the wall. Never jet the stream directly onto the lyophilised cake.
- Invert, do not shake. Rotate gently until fully dissolved. Foam indicates surface denaturation.
- Check clarity. Discard any solution showing opalescence or visible particulates.
- Aliquot immediately. Single-use aliquots avoid repeated warming of the working stock.
- Record everything. Compound, batch, concentration in mg/mL, diluent and date on every tube.
| Mass in vial | Diluent added | Resulting concentration | Amount per 0.1 mL |
|---|---|---|---|
| 5 mg | 1.0 mL | 5.0 mg/mL | 500 mcg |
| 5 mg | 2.0 mL | 2.5 mg/mL | 250 mcg |
| 10 mg | 1.0 mL | 10.0 mg/mL | 1000 mcg |
| 10 mg | 2.0 mL | 5.0 mg/mL | 500 mcg |
| 10 mg | 4.0 mL | 2.5 mg/mL | 250 mcg |
| 15 mg | 3.0 mL | 5.0 mg/mL | 500 mcg |
Choosing a reference compound
The right compound follows from the receptor question. The series is most powerful when used as a series: comparing all three under identical conditions isolates the contribution of each additional receptor arm far more cleanly than any single compound can.
Isolating GLP-1R
Semaglutide is the cleaner tool — one receptor, one signal, the largest published structure–activity dataset, and a well-defined mass for identity confirmation.
Testing GIPR contribution
Tirzepatide against semaglutide, under matched conditions, isolates the incremental GIPR arm. Remember the bias: differences may reflect signalling character, not only receptor count.
Testing the glucagon arm
Retatrutide against tirzepatide isolates the GCGR contribution. Including a GLP-1R/GCGR dual agonist such as mazdutide or survodutide as a fourth arm strengthens the design further.
Practical selection
Match vial sizes so that stock concentrations can be made identical, and source all three from the same supplier and, ideally, comparable batch dates to minimise between-batch variance.
The three compounds in the GenoPept store
Frequently asked questions
What is the main difference between semaglutide, tirzepatide and retatrutide?
Receptor coverage. Semaglutide activates the GLP-1 receptor only. Tirzepatide activates both the GIP receptor and the GLP-1 receptor from a single molecule. Retatrutide activates GLP-1R, GIPR and the glucagon receptor. Semaglutide is built on a GLP-1 backbone; tirzepatide and retatrutide are 39-residue peptides built on a GIP-derived scaffold.
Is retatrutide stronger than tirzepatide?
They are not directly comparable, because no randomised head-to-head trial between them has been published. The retatrutide phase 2 trial reported a larger mean change in body weight than the SURMOUNT-1 tirzepatide trial, but the studies differed in duration, population and design, so any comparison is cross-trial and should be treated as weak evidence.
Why is tirzepatide called an imbalanced agonist?
Because its potency at its two target receptors differs substantially. Published receptor characterisation reports near-native potency at GIPR but markedly weaker activity at GLP-1R, alongside a bias towards G-protein signalling over β-arrestin recruitment at GLP-1R. This means tirzepatide is not pharmacologically equivalent to combining a selective GIP agonist with a selective GLP-1 agonist.
Do semaglutide, tirzepatide and retatrutide have the same molecular weight?
No. Semaglutide is the smallest at 4113.6 Da with 31 residues. Tirzepatide is approximately 4813 Da and retatrutide approximately 4731 Da, both with 39 residues. The difference matters whenever an assay is designed around molar rather than mass concentration, because equal masses give unequal molar amounts.
Can these three peptides be reconstituted the same way?
Yes. All three are acylated, surface-active peptides supplied as lyophilised powder and follow identical handling rules: warm the vial, add diluent gently down the wall, dissolve by slow inversion rather than shaking, inspect for clarity, and aliquot for single use. Bacteriostatic water is the usual diluent for a multi-draw laboratory stock.
Which is the best reference compound for GLP-1 receptor work?
Semaglutide, in most cases. As a mono-agonist it produces a signal attributable to a single receptor, its structure–activity relationship is the most thoroughly published of the three, and its molecular weight is well established for mass-spectrometric identity confirmation. Dual and triple agonists are better suited to questions about receptor interaction.
What does a glucagon receptor arm add?
In published discussion, GCGR agonism is associated with hepatic glucose and lipid handling and with a contribution to energy expenditure. Because glucagon and GLP-1 have opposing glycaemic effects, a triple agonist must be deliberately imbalanced — weaker at GCGR than at the incretin receptors — so the glucagon arm contributes without offsetting glycaemic control.
Are these compounds supplied for human use?
No. Semaglutide, tirzepatide and retatrutide are supplied by GenoPept strictly for in-vitro laboratory research and analytical work. They are not medicines, are not manufactured to pharmaceutical standards, and must not be used for human or veterinary purposes or for the diagnosis, treatment or prevention of any condition.
References
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018;27(4):740–756. PubMed
- Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015;58(18):7370–7380. Publisher
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism. 2018;18:3–14. PubMed
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5:e140532. PubMed
- Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proceedings of the National Academy of Sciences. 2022;119(13):e2116506119. Publisher
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002. PubMed
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389:514–526. PubMed
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205–216. PubMed
Also cited in Table 2: Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021;385:503–515 (PubMed).
Research-grade semaglutide, tirzepatide and retatrutide
GenoPept supplies all three compounds as lyophilised vials with a per-batch third-party certificate of analysis covering HPLC purity and mass-spectrometric identity, dispatched from the UK strictly for laboratory research.